Balyasny Asset Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | – | Sell |
-70,502
| Closed | -$108K | – | 1947 |
|
2025
Q1 | $108K | Buy |
+70,502
| New | +$108K | ﹤0.01% | 1902 |
|
2024
Q3 | – | Sell |
-13,910
| Closed | -$15.3K | – | 1909 |
|
2024
Q2 | $15.3K | Buy |
+13,910
| New | +$15.3K | ﹤0.01% | 1846 |
|
2023
Q4 | – | Sell |
-10,511
| Closed | -$72K | – | 1868 |
|
2023
Q3 | $72K | Buy |
+10,511
| New | +$72K | ﹤0.01% | 1661 |
|
2023
Q1 | – | Sell |
-20,503
| Closed | -$323K | – | 2144 |
|
2022
Q4 | $323K | Sell |
20,503
-85,644
| -81% | -$1.35M | ﹤0.01% | 1542 |
|
2022
Q3 | $1.67M | Buy |
+106,147
| New | +$1.67M | 0.01% | 1208 |
|
2022
Q2 | – | Sell |
-209,636
| Closed | -$3.61M | – | 2245 |
|
2022
Q1 | $3.61M | Sell |
209,636
-256,764
| -55% | -$4.43M | 0.01% | 847 |
|
2021
Q4 | $6.78M | Buy |
466,400
+304,557
| +188% | +$4.43M | 0.02% | 630 |
|
2021
Q3 | $2.91M | Buy |
161,843
+7,423
| +5% | +$134K | 0.01% | 830 |
|
2021
Q2 | $2.71M | Buy |
+154,420
| New | +$2.71M | 0.01% | 818 |
|
2019
Q1 | – | Sell |
-315,167
| Closed | -$2.33M | – | 1266 |
|
2018
Q4 | $2.33M | Sell |
315,167
-274,833
| -47% | -$2.03M | 0.02% | 601 |
|
2018
Q3 | $8.57M | Sell |
590,000
-110,111
| -16% | -$1.6M | 0.04% | 437 |
|
2018
Q2 | $14M | Sell |
700,111
-285,865
| -29% | -$5.71M | 0.06% | 343 |
|
2018
Q1 | $17.3M | Buy |
985,976
+58,059
| +6% | +$1.02M | 0.07% | 318 |
|
2017
Q4 | $22.9M | Buy |
927,917
+461,340
| +99% | +$11.4M | 0.07% | 325 |
|
2017
Q3 | $12M | Buy |
466,577
+46,577
| +11% | +$1.2M | 0.05% | 379 |
|
2017
Q2 | $11.4M | Buy |
420,000
+21,250
| +5% | +$576K | 0.05% | 427 |
|
2017
Q1 | $11.9M | Buy |
398,750
+48,750
| +14% | +$1.45M | 0.06% | 377 |
|
2016
Q4 | $9.5M | Buy |
350,000
+250,798
| +253% | +$6.81M | 0.05% | 400 |
|
2016
Q3 | $2.54M | Buy |
+99,202
| New | +$2.54M | 0.01% | 585 |
|